Eledon Q3 net loss of $9.8M ($0.66/sh); pipeline progress in ALS, IgAN, transplant

Eledon Pharmaceuticals, Inc.

2022-Q3 EPS reported -$1.73

Net loss of $9.8M for Q3 2021 vs $6.1M; R&D expenses surged to $7.7M from $0.6M.
Cash of $94.0M as of Sept 30, 2021; company funded into 2023.
Phase 2 ALS study nearing full enrollment; topline data expected 1H 2022.
IND clearance for AT-1501 in islet cell transplantation; kidney and IgAN trials expected Q4 2021 start.
Research collaboration with CareDx for renal transplant biomarkers and predictive algorithms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.